TENX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.415

+130.56%

-0.425

+51.79%

-0.430

+59.26%

Estimates Revision

The market is revising No Change the revenue expectations for Tenax Therapeutics, Inc. (TENX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 78.28%.

EPS Estimates for FY2025

Revise Downward

-65.94%

In Past 3 Month

Stock Price

Go Up

+78.28%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast TENX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TENX is 25.00 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

25.00

High

30.00

Current: 0.000

Low

20.00

Averages

25.00

High

30.00

Guggenheim

NULL -> Buy

maintain

$14 -> $25

2025-12-17

Reason

Guggenheim

Price Target

$14 -> $25

2025-12-17

maintain

NULL -> Buy

Reason

Guggenheim raised the firm's price target on Tenax Therapeutics to $25 from $14 and keeps a Buy rating on the shares. The firm is reiterating Tenax as a Top Pick for 2026 as it nears its first pivotal readout for oral levosimendan in pulmonary hypertension caused by heart failure with preserved ejection fraction in the second half of next year, the analyst tells investors.

Piper Sandler

Yasmeen Rahimi

Overweight

initiated

$20

2025-09-08

Reason

Piper Sandler

Yasmeen Rahimi

Price Target

$20

2025-09-08

initiated

Overweight

Reason

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tenax Therapeutics with an Overweight rating and $20 price target. The company is s developing TNX-103 in pulmonary hypertension associated with heart failure with preserved ejection fraction with the Phase 3 LEVEL readout expected in the second half of 2026, the analyst tells investors in a research note. The firm believes Tenax is \"flying under the radar\" despite having the potential win approval in a high unmet need indication.

Guggenheim

Seamus Fernandez

Buy

downgrade

$16 -> $15

2025-05-15

Reason

Guggenheim

Seamus Fernandez

Price Target

$16 -> $15

2025-05-15

downgrade

Buy

Reason

Guggenheim analyst Seamus Fernandez lowered the firm's price target on Tenax Therapeutics to $15 from $16 and keeps a Buy rating on the shares. The firm, which is updating its model following the company's Q1 results, looks forward to the Phase 3 LEVEL readout in 2026. The firm believes this data will be "a major catalyst from which we see the potential for at least a 2x stock move from current levels," the analyst added.

Valuation Metrics

The current forward P/E ratio for Tenax Therapeutics Inc (TENX.O) is -6.48, compared to its 5-year average forward P/E of -1.86. For a more detailed relative valuation and DCF analysis to assess Tenax Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.86

Current PE

-6.48

Overvalued PE

-0.35

Undervalued PE

-3.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.01

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.26

Undervalued EV/EBITDA

-0.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.41

Current PS

0.00

Overvalued PS

1.69

Undervalued PS

-0.88

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TENX News & Events

Events Timeline

No data

News

4.0

2025-12-21NASDAQ.COM

Tenax Therapeutics (TENX) Price Target Raised by 12.22% to 25.76

2.0

2025-12-17Newsfilter

Tenax Initiates Global LEVEL-2 Study, Enrollment Expected by 2027

2.0

2025-12-17Globenewswire

Tenax Initiates Global LEVEL-2 Study, Enrollment Expected by 2027

People Also Watch

Frequently Asked Questions

What is Tenax Therapeutics Inc (TENX) stock price today?

The current price of TENX is 13.3 USD — it has increased 1.37 % in the last trading day.

What is Tenax Therapeutics Inc (TENX)'s business?

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

What is the price predicton of TENX Stock?

What is Tenax Therapeutics Inc (TENX)'s revenue for the last quarter?

Tenax Therapeutics Inc revenue for the last quarter amounts to -16.81M USD, increased 263.85 % YoY.

What is Tenax Therapeutics Inc (TENX)'s earnings per share (EPS) for the last quarter?

Tenax Therapeutics Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Tenax Therapeutics Inc (TENX)'s fundamentals?

How many employees does Tenax Therapeutics Inc (TENX). have?

Tenax Therapeutics Inc (TENX) has 4 emplpoyees as of January 10 2026.

What is Tenax Therapeutics Inc (TENX) market cap?

Today TENX has the market capitalization of 83.04M USD.